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Despite the combined action of surgery, radiotherapy and chemotherapy, the leading cause of death in cancer patients continues to
be the acquired, or intrinsic, tumour resistance to therapy. Some of the genetic alterations that contribute to the malignant
transformation are involved in maintaining cell survival under uncontrolled growth conditions. Chemotherapy agents, as well as
radiotherapy, trigger a series of signalling pathways in the cells that activate not only the apoptotic machinery, but also cell-survival
pathways. In this scenario, the efficacy of therapy is the result of balance between the apoptotic and the survival pathways activated in
the tumour, and those elicited by the therapeutic agent. Apoptosis is one of the programmes usually altered in most cancers so as to
guarantee tumour progression and, often, these alterations are responsible for therapy resistance, as well.
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ONCOGENIC TRANSFORMATION AND SURVIVAL
PATHWAYS
Therapy resistance mechanisms that tumour cells develop are
complex and can be acquired during, or after, treatment. This
aggressive behaviour is often derived from survival pathways
activated during malignancy progression and driven by oncogenic
transformation. There are several examples of oncogenes that can
activate such survival pathways, and among these are ras, src, raf,
kit, together with the amplification of HER2 and EGFr. The
paradigm of these oncogenes is ras, because of the involvement of
mutations in ras itself in about 20% of human tumours. In other
cases, EGFr overexpression or HER2-neu amplification positively
regulate ras signalling pathways (Downward, 2003). Both, EGFr
and Her2 expression are altered in many types of cancer, including
those of the breast, ovary and stomach. Additionally, truncation of
the EGFr, which results in deletion of the extracellular domain, is
found in a significant proportion of glioblastomas and other
tumour types. The EGFr family of tyrosine kinases is also activated
by the autocrine production of EGF-like factors, such as TGF-a,i n
tumours. In addition to the raf/MAPK pathway involved in cell
cycle activation, ras directly activates the catalytic subunit of the
type I phosphatidylinositol-3 kinase (PI3K) that leads to the
production of phosphatidylinositol 3,4,5 triphosphate, a second
messenger that interacts with a large number of downstream
enzymes such as AKT/PKB. AKT has a strong antiapoptotic action
by phosphorylating several targets, and is the main survival
pathway activated by ras. The mechanism by which AKT protects
cells from apoptosis is by its ability to phosphorylate several
components of the cell-death machinery (Vivanco and Sawyers,
2002). AKT inhibits the catalytic activity of caspases by
phosphorylation. Bad, a proapoptotic member of the bcl2 family
of proteins, is also phosphorylated by AKT, thus preventing its
interaction with bclxl and abolishing its proapoptotic function.
AKT also phosphorylates FKHR, a member of the forkhead family
of transcription factors, thus preventing its nuclear translocation
and inhibiting expression of its targets that include several
proapoptotic proteins such as FasL and Bim. Finally, AKT
phosphorylates p65, a subunit of the NFKB transcription factor,
thus enhancing its transactivation potential and facilitating the
expression of several antiapoptotic genes such as BCLxl, and the
cIAP family of caspase inhibitors.
Different components of the PI3K pathway are also mutated in
several types of tumours. The gene encoding p105, the catalytic
subunit of PI3K, is found to be amplified in some ovarian cancers,
while AKT has been observed to be amplified in ovarian and breast
cancer (Ruggeri et al, 1998). PTEN, a 3-lipid phosphatase that
converts PIP3 back to PIP2, acting as a suppressor gene, is deleted
or mutated in several human cancers including those of the breast
and endometrium, hepatocellular carcinomas, glioblastomas, lung
cancer, renal carcinoma and thyroid tumours (Ali et al, 1999).
Several preclinical studies have reported a direct correlation
between oncogenic transformation and drug resistance. Examples
are the increase in resistance to radiation in bladder carcinomas
induced by ras mutations, to CPT-11 and gemcitabine in colon
cancer, to gemcitabine in pancreatic carcinoma, and to radiation
and BCNU in glioblastomas (Chakravarti et al, 2002). In most of
these cancers, resistance to therapy is due to upregulation of PI3K
activity. In breast cancer, amplification of HER2 is associated with
taxol resistance (Witters et al, 2003), and in glioblastomas increase
in EGFr activity to radiation and BCNU (Chakravarti et al, 2002).
Some clinical studies have shown correlations between ras and
myc mutations and resistance to therapy in ovarian cancer, and
overexpression of EGFr in breast cancer. However, further studies
are needed to provide a better overview of the problem, at the
clinical level.
c-kit is a type II tyrosine kinase that activates different signalling
pathways in response to the ligand: stem cell factor. Mutations in
the catalytic activity domain in the cytoplasmic region are
associated with transformation in patients with gastrointestinal
Received 4 August 2003; revised 4 November 2003; accepted 11
November 2003
*Correspondence: R Perona; E-mail: RPerona@iib.uam.es
British Journal of Cancer (2004) 90, 573–577
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.comtumours (GIST), a very resistant type of cancer (Hirota et al, 1998).
Among the different signalling pathways associated with c-kit
activation is the PI3K/Akt survival pathway that contributes to
resistance to the different treatments.
p53, a tumour-suppressor gene, plays a central role in DNA
damage detection, cell cycle transitions and apoptosis control in
response to damage. Since most of the treatment protocols include
DNA-damaging agents, the function of p53 is very important in
therapeutic response. About 50% of all human cancers harbour
mutations in the p53 gene, which affect its ability to activate
expression of proapoptotic genes. Conversely, tumours that retain
wild-type p53 frequently have modifications and/or defects in the
pathways that facilitate the stabilisation of p53 in response to
stress. p53 regulates transcription of genes that regulate both the
mitochondrial as well as the receptor-activated apoptotic pathways
such as APAf-1, Bax, NOXA, PERP, PTEN, PUMA, FAS, etc
(Schuler and Green, 2001). p53-mediated activation of apoptotic
target genes is also regulated by cofactors such as JMY, ASPP, and
other members of the p53 family, p63 and p73. Both the JMY as
well as the ASPP family of proteins have been shown, recently, to
interact with p53 and to enhance the promoters of apoptotic target
genes such as bax. IASPP1 is an evolutionary-conserved inhibitor
of p53 that works as a transforming protein which co-operates with
ras, E1A and E7 to transform cells in vitro. Enforced expression of
IASPP confers resistance to radiation and cisplatin-induced
apoptosis. IASPP expression is upregulated in human breast
carcinomas expressing wt p53 and normal levels of ASPP
(Bergamaschi et al, 2003).
At the clinical level, the role of p53 and drug resistance has been
extensively evaluated by assessing clinical status in relation to
response to chemotherapy and overall survival. Although in some
studies correlations have been found between tp53 mutations and
chemoresistance, such as in lung and ovarian carcinomas, in other
types of tumours, the correlation has not been as clear and is due,
possibly, to the involvement of other genetic changes that have
accumulated in these tumours.
SIGNAL TRANSDUCTION PATHWAYS ACTIVATED
BY THERAPY: APOPTOSIS VS SURVIVAL
Apart from surgery, cancer treatment is based, mainly, on
chemotherapy and radiotherapy, and both are cytotoxic agents
that induce apoptosis in target cells. Since most cancers are not
sensitive to these treatments, the resistance that is developed
becomes a major problem at the clinical level. Further, when
tumours relapse, the response to treatment is lower than that of the
initial tumour. Most antitumour drugs, and also g-radiation, are
DNA-damaging agents. Since cells are routinely exposed on a daily
basis to many such damaging agents, the principal targets of which
are proteins and DNA, they develop different mechanisms in an
attempt to minimise, or to resolve, any damage before the mitotic
process commences. This is so as to pre-empt deleterious
mutations being inherited in the daughter cells. Exposure of cells
to therapeutic genotoxic agents initiates a series of events leading
to activation of a wide range of signalling pathways that regulate
cell cycle repair as well as apoptosis, and involves a wide group of
genes with diverse functions. Current knowledge of cancer
indicates that it is a complicated disease in which, depending on
the type of tumour, many pathways are deregulated. Chemother-
apy and radiation activate signalling pathways which can be
rapidly induced, as well, in response to mitogenic stimulation and
which, sometimes, are the same as those that are deregulated in the
tumour. Consequently, it is important for the clinician to know the
mechanisms by which apoptosis can be induced so that the balance
of the signalling pathways may be tipped towards apoptosis.
Although the primary intracellular targets –of action of
chemotherapy agents are different, it has become evident that
induced cytotoxicity converges, ultimately, on a common pathway
that induces apoptosis. Most of these pathways involve the
activation of protein kinases. These include the nonreceptor
tyrosine kinase c-abl, Lyn, the mitogen-activated protein kinase
(MAPK) family, the transcription factor NFkB and the checkpoint
proteins. In evolutionary terms, the MAPK pathway is highly
conserved, which includes the ERK, JNK and p38 family. These are
organised in a module of three kinases that are activated by a
phosphorylation cascade. Each MAP kinase subfamily is activated
by a specific upstream MAP kinase kinase (MKKs), which
phosphorylates the threonine as well as the tyrosine residues
within a conserved T–X–Y motif. Activation of the MAP kinase
family members leads to phosphorylation of several cellular
effector molecules, including protein kinases such as MAPKAPK1,
MAPKAP-K2/3, Mnk1/2, as well as transcription factors such
as c-jun, ATF-2, MEF2c and CHOP, all of which influence the fate
of the cell.
The MAPKs are conserved proteins that regulate the
growth, division and death of the cell. The MAPK pathway
represents a cascade of phosphorylation events including
three pivotal kinases, namely Raf, MEK (MAP kinase kinase)
and ERK (MAP kinase). Activation of ERK by chemotherapy
agents is controversial and, ultimately, depends on the type of
tumour. Cisplatin, an antitumour agent that is widely used
in the treatment of several kinds of solid tumours has been
shown to cause activation of ERK in ovarian carcinoma
(Hayakawa et al, 1999), neuroblastoma and HeLa cells, but
not in keratinocytes. Inhibition or ERK activation results in
increased sensitivity to cisplatin and taxol-induced cell death
in ovarian cancer cell lines and some melanoma cell lines
(Mandic et al, 2001), but can result in an increased resistance to
cisplatin in HeLa cells.
Activation of the Jun-N-terminal kinase (JNK) pathway has been
implicated in apoptotic response to DNA damage, cell stress and
cytotoxic drugs. It appears that, in normal cells, the activation of
JNK is a proapoptotic event and drives the activation of
proapoptotic members of Bcl-2 family, causing an induction of
cytochrome c release from the mitochondria. However, there is less
consensus regarding the roles of JNK and of c-Jun in tumour cells.
The initiation of mitochondrial apoptosis pathways by JNK is
independent of its transcription effects, for the most part. In
certain cell types, c-Jun overexpression is clearly a basis for
resistance to DNA-damaging drugs, and resistance reversal has
been observed using antisense RNA against c-Jun (Hayakawa et al,
1999). Conversely, in other cell systems, the absence of c-Jun
makes cells more resistant to cisplatin treatment (Sanchez-Pe ´rez
and Perona, 1999). As such, there is still considerable controversy
regarding JNK activation and its role in apoptosis and/or survival.
Both mechanisms are not mutually exclusive, since certain
parameters, such as the timing of the signal, could be important.
Sustained JNK activation is required for apoptotic signalling and is
sufficient for apoptosis in response to cisplatin and irradiation. In
contrast, TNF-a causes transient JNK activation and apoptosis is
not induced in some cell lines (Liu et al, 1996). These
considerations indicate that transient JNK activation (or elevated
basal JNK activity) may be important for mediating a survival
response to stress, and that chronic JNK activation may contribute
to an apoptotic response. A second aspect to consider is the
crosstalk between different pathways. For example, the activation
of AKT can suppress the apoptotic effects of activated JNK (Kim
et al, 2002) or, alternatively, JNK may modulate other signalling
pathways that mediate cell survival, such as NF-kB (Sanchez-Pe ´rez
et al, 2002). Target genes that have AP1 and NF-kB-responsive
elements in their promoters could be differentially expressed
according to the relative activity of the different pathways.
Recently, Lamb et al (2003) reported that JNK activation, in
response to TNF-a, increases together with c-jun and JunD levels.
As a consequence, JunD induces c-IAP-2 transcription, while, at
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to JNK activation.
NF-kB comprises a family of inducible transcription factors that
act as regulators of the host immune and inflammatory responses.
Also, they have been involved in protecting cells from apoptosis
induced by chemotherapy agents, or cytokine treatment. NFKB is a
heterodimer composed, among others, of p50 and p65/RelA
subunits (Karin et al, 2002). In nonstimulated cells, NF-kBi s
found, mainly, in the cytoplasm, in association with a family of
inhibitory molecules known as the IKBs. The activation mechan-
ism of NF-kB involves phosphorylation of the IKBs via the IKB
kinase (IKK) signalosome complex. Two different kinases that
phosphorylate the IKKs have been described: NFKB-induced
kinase and MEKK1. Once the IKBs have been phosphorylated,
they are targeted for ubiquitin binding and subsequent degrada-
tion by the 26-S proteosome. Free p50/p65 heterodimers
translocate to the nucleus, where they activate transcription of
NFKB-responsive genes. Most of these genes such as BCLxl, XIAP,
c-IAP-1,2 and FasL (Orlowski and Baldwin, 2002) are involved in
apoptosis induction. Chemotherapy agents such as doxorubicin,
cisplatin and taxol, among others, induce survival signals,
depending on NFkB transcription and on the apoptosis pathways,
driven mainly by JNK and p38.
A protein that is key in transducing the DNA damage signals to
apoptosis is p53. Most chemotherapy agents, and g-radiation,
induce stabilisation and activation of p53. The transcription
activity of p53 is important for its apoptotic functions, since it
induces the expression of proteins directly involved in apoptosis,
such as BAX, NOXA, PUMA, CD95, TRAIL-R1 and TRAIL-R2.
Since p53 is mutated in nearly 50% of human tumours, induction
of apoptosis by chemotherapy agents in these tumours can be
compromised.
STRATEGIES FOR OVERCOMING THERAPY
RESISTANCE
Over the past decade, numerous strategies have been designed to
modulate signalling pathways activated by oncogenes in an effort
to inhibit cell growth in very specific ways. Since genetic
alterations that accumulate in tumours favour survival of cells
exposed to different stress conditions, the response to therapy
frequently becomes severely compromised. New molecules that
influence specific signalling pathways administered in combina-
tion with cytotoxic drugs have become the preferred strategies in
preclinical and clinical studies in an attempt to overcome intrinsic
drug resistance. We shall, now, proceed to describe some of these
strategies.
Restoring p53 activity in tumour cells has a therapeutic
potential because p53 is lost in many tumours and results in
resistance to platinum compounds and radiotherapy. Different
approaches have been tried in restoring wtp53 activity. These
include gene transfer of wtp53 and chemical restoration of
wt activity. Gene transfer has been accomplished by using
replication-deficient adenoviral vectors that express wtp53.
Different preclinical studies have demonstrated synergistic
activity between re-expression of p53 and chemotherapy in the
patient’s response to therapy (Nielsen and Maneval, 1998). The
combination of wtp53 gene transfer and chemotherapy with
cisplatin, doxorubicin, 5-FU, methotrexate or etoposide in
human xenograft tumour animal models of the lung, breast, head
and neck, prostate and ovarian cancer produced significantly
greater apoptosis and tumour growth suppression than any of
the drugs alone (Lebedeva et al, 2003). These results have
encouraged clinical studies in patients with advanced cancer. At
the NIH database, there are, currently, 29 clinical trials employing
wtp53 gene transfer in different types of cancers. Some of these
trials show that NSCLC treated with cisplatin, vinorelbine or a
combination of both resulted in stabilisation, and regression, of
tumours. With respect to ovarian cancer, the one study that
used cisplatin resulted in an increased median survival com-
pared to chemotherapy alone. Although the results are promising,
the limitation of this approach is linked to the development of
new and improved vectors that are not toxic, nonimmunogenic
and which can transfer the gene to a high proportion of cancer
cells.
An alternative approach that has been used to restore p53
activity is the use of small molecules that modify the p53 mutant
strain back to wildtype. CP-31398, a styrylquinazoline, restores a
wild-type DNA-binding conformation of mutant p53, and is able to
suppress tumour growth in vitro and in vivo. CP-31398 induces
apoptosis in p53 mutant cancer cells by activating the bax/
mitochodrial/caspase-9 pathway, suggesting that it can also
sensitise tumour cells to cytotoxic drug treatment (Luu et al, 2002).
Targeting the growth factor receptors that are involved in the
survival of cancer cells has become a potential strategy for
apoptosis induction, either as a single treatment or in combination
with traditional therapies. One potential therapeutic target is the
epidermal growth factor receptor (EGFr) superfamily. Many
different strategies that interrupt EGFr-dependent signalling have
been investigated. Monoclonal antibodies have been developed
that target members of the EGFr family. These include antibodies
to EGFr and monoclonal antibodies to HER2. Cetuximab, a
human-murine chimeric IgG monoclonal antibody, competitively
binds to the extracellular domain of EGFr, thus preventing tyrosine
kinase activation and inducing apoptosis (Herbst and Langer,
2002). Preclinical studies have demonstrated that, in cell lines
expressing EGFr as well, there is an increase in the cytotoxic
activity of chemotherapy and radiation (Robert et al, 2001).
Clinical studies in patients with NSCLC and head and neck cancer
are in progress using this antibody in combination with
chemotherapy. Trastuzumab (Herceptin), a monoclonal antibody
against the extracellular domain of HER2, was designed for use in
breast cancers in which HER2 amplification occurs more
frequently. A phase III clinical trial for patients with metastatic
breast cancer with overexpression of HER2 demonstrated that the
addition of trastuzumab to chemotherapy was associated with a
delayed time to -progression of the disease (Azzoli et al, 2002).
HER2 is found amplified in lung adenocarcinomas and large-cell
carcinomas as well, and is predictive of poorer outcomes. Clinical
trials with HER2-positive patients with advanced NSCLC failed to
improve treatment outcome for most of the patients in the trial,
although a small percentage, in whom HER2 was found to be
positive by fluorescence in situ hybridisation (FISH), responded to
treatment.
Tyrosine kinase inhibitors to EGF receptors have been devel-
oped that compete with and prevent the binding of adenosine
triphosphate to the tyrosine kinase region. In preclinical studies,
these agents cause inhibition of cell proliferation and induce
apoptosis in EGFr-positive cell lines. Gefitinib (ZD1839, Iressa),
one of the agents currently in the most advanced stage of
development, has shown encouraging results in preclinical studies
when combined with chemotherapy in NSCLC. The clinical trials
in patients with stage III/IV NSCLC using gefinitib, in combination
with gemcitabine and cisplatin, failed to demonstrate any
improvement in survival rates. Although other clinical studies,
with a more strict selection of patients, have been conducted, it is
still not clear if the expression of EGFr is necessary for response, or
whether its inhibition will represent a clinical benefit of treatment
in NSCLC.
Therapeutic targeting of ras has been approached by inhibiting
the covalent attachment of the farnesyl-isoprenoid group to the H-
ras, K-ras and N-ras proteins, the first steps in the carboxy-
terminal post-translational modification of these proteins. The
farnesyltransferase inhibitors (FTIs) that have been developed to
target RAS also inhibit the farnesylation of other proteins and
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growth are due to inhibition of the RAS-related protein RHOB
(Prendergast, 2001). This issue, however, remains unresolved at
present. Farnesyltransferase inhibitors have shown important
effects in growth and survival of some tumour cell lines in vitro
and in xenografts in nude mice. Although the results of preclinical
studies have been promising, clinical studies have faced several
stumbling blocks in their efforts to demonstrate their usefulness in
common cancers. Nevertheless, some interesting results have
emerged from clinical trials in patients with chronic myeloid
leukaemia and other haematological malignancies. Also, in
preclinical studies, FTI-277 has been demonstrated to inhibit
growth and induce apoptosis in drug-resistant myeloma cells as
well as in gliomas when combined with radiotherapy. Interestingly,
SCH66336 has been shown to enhance chemosensitivity of human
and mouse melanoma cells to cisplatin, and to overcome STI571
resistance in BCR-ABL-positive cells. These results suggest that
combination therapy may be more effective in patients with STI-
571 resistance (Hoover et al, 2002).
The survival-signalling pathway, whose components are sub-
jected to more frequent deregulation in cancer, is that of the PI3K/
AKT pathway, and the consequences of this process contribute to
malignancy progression as well as to treatment resistance. As such,
chemical inhibitors of AKT have a potential use as suppressors of
tumour growth. Early generation examples of this type of
compound (wortmannin and LY294002 which inhibit the catalytic
activity of p110) have been studied extensively in in vitro assays.
LY294002 administration in mouse tumour models has been
shown to confer antitumour activity and to enhance the
cytotoxicity of treatment with taxol and radiotherapy (Hu et al,
2002). Interestingly, in human breast cancer cells, inhibition of
PI3K by LY294002 blocks the resistance induced by ras
transformation (Jin et al, 2003). The use of rapamycin, an
immunosuppressant drug already being used in the clinic and
which is an inhibitor of the AKT substrate, mTOR kinase, has
opened up the possibility of indirectly inhibiting akt survival
pathways. Derivatives of rapamycin, such as CCI-779, have been
shown to inhibit the tumour growth of several PTEN-negative
tumour cells in vitro and to increase the cytotoxic activity of
traditional therapies, Neshat et al (2001). In view of the results
obtained with wortmannin, LY294002 and rapamycin derivatives,
several drug-discovery programs are underway. The search is for
small-molecule inhibitors of PI3K and several other kinases in the
pathway, including PDK1 and the integrin-linked kinase (ILK),
which might be equally important in keeping the AKT pathway
activated.
Activation of the NF-kB-dependent transcription itself, or
as a consequence of activated ras/PI3K/AKT pathway, occurs in
several human tumours. Additionally, some antitumour agents
such as paclitaxel and cisplatin, among others, have induced cell
survival via this pathway. Adenovirus-mediated inhibition of NF-
kB elicited by the IKB super-repressor protein abrogate the
chemoresistance of some types of tumours such as androgen-
independent prostate cancer cells and glioma-derived cell lines
(Orlowski and Baldwin, 2002). Work is in progress in several
laboratories to isolate small molecules that inhibit the IKKs, and
whose activities in some tumours lead to constitutive NF-kB
activation and in others, such as breast cancer, where IKKa plays
an important role in proliferation. Finally, targeting of IAPs
resulting in upregulation by means of the NFKB pathway has been
approached via the activation of the apoptosis-ligand receptors of
the Apo2/TRAIL, most normal cells being resistant to treatment
with TRAIL while cancer cell lines are sensitive to Apo2/TRAIL.
Chemotherapy and/or radiation could sensitise TRAIL-induced
apoptosis in vitro as well as in vivo. More recently, smac/diablo-
derived peptides, have been shown to sensitise tumour cells to
Apo2/TRAIL or anticancer drug-induced apoptosis in gliomas in
vivo (Fulda et al, 2002).
FUTURE DIRECTIONS
At the preclinical as well as the clinical level, the problem of drug
resistance is still unresolved. Many different approaches have been
taken using tumour-derived cell lines and inhibiting signalling
pathways activated by oncogenes that participate in cell survival by
the administration of combinations of chemotherapy and radio-
therapy (Figure 1). One issue that remains unresolved is that of the
relative importance of these pathways for tumour survival in vivo,
and how they co-operate with genetic changes in the apoptotic
machinery in order to ensure tumour progression. Hopefully,
more knowledge of the genetic changes that contribute to
malignancy in each tumour will be acquired soon, using genomic
and proteomic techniques. This would also help in the identifica-
tion of profiles of expression associated with drug sensitivity or
resistance, and this information is used to decide the drug to be
used as a first choice. With current knowledge, there are several
candidate genes to be taken into consideration, whose activity
would be predictive of poor response. Among them are AKT itself
and genes that regulate AKT activity, such as PTEN. In this
context, several additional aspects need to be taken in considera-
tion. These involve the activity of genes implicated in DNA repair
that can condition the efficiency of drug activity in target cells.
Last, but not least, therapies that include inhibition of oncogene-
dependent pathways in combination with traditional therapies and
upregulation of apoptosis in tumours by alternative routes (Apo2/
TRAIL, smac/diablo) will, undoubtedly, contribute to the reversal
of resistant phenotypes.
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Figure 1 Combination therapy would shift the balance towards
apoptosis in the response of drug-resistant tumours. Note: In normal cells,
the balance among apoptosis and survival signals allow controlled
homeostasis of the tissue. In cancer cells, survival signals triggered by
oncogenic transformation favour uncontrolled growth. Traditional treat-
ments such as chemotherapy and radiotherapy, together with targeted
therapies, are still not sufficient to kill tumour cells efficiently due to the
existence of antiapoptotic mechanisms in the tumour. Reactivation of the
apoptotic machinery by strategies such as Apo2/TRAIl delivery would,
probably, make the combination of traditional and targeted therapies more
efficient.
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